The value of circulating long non-coding RNA maternally expressed gene 3 as a predictor of higher acute respiratory distress syndrome risk and 28-day mortality in sepsis patients

Xiaoling Wu | Dan Chen | Li Yu

Abstract

Objective: This study was to evaluate the potential of long non-coding RNA maternally expressed gene 3 (lncRNA MEG3) in predicting acute respiratory distress syndrome (ARDS) risk and its correlation with prognosis in sepsis patients.

Methods: The plasma samples were obtained from 112 sepsis patients within 24 hours after admission and 100 healthy controls (HCs) at enrollment. The lncRNA MEG3 expression in plasma samples was determined by RT-qPCR. In sepsis patients, ARDS occurrence was assessed based on Berlin definition of ARDS and 28-day mortality risk was evaluated.

Results: LncRNA MEG3 expression was increased in sepsis patients compared with HCs. During 28-day duration, 30 sepsis patients occurred ARDS and 82 sepsis patients did not occur ARDS. LncRNA MEG3 expression was elevated in ARDS sepsis patients compared with non-ARDS sepsis patients, then the following receiver-operating characteristic (ROC) curve analysis disclosed that lncRNA MEG3 predicted ARDS risk (area under the curve (AUC) = 0.775), which was further validated as an independent risk factor by multivariate logistic regression. Furthermore, lncRNA MEG3 was positively correlated with chronic obstructive pulmonary disease, respiratory infection, acute physiology and chronic health evaluation II score, sequential organ failure assessment score, white blood cell, and C-reactive protein, while negatively correlated with albumin in sepsis patients. Additionally, lncRNA MEG3 was elevated in 28-day deaths compared with 28-day survivors, and it predicted 28-day mortality risk in sepsis patients (AUC = 0.708) by ROC curve analysis.

Conclusion: LncRNA MEG3 might represent as a valuable biomarker for individualizing prevention strategies against ARDS and improving prognosis in sepsis.

KEYWORDS

ARDS, disease severity, LncRNA MEG3, prognosis, sepsis
1 | INTRODUCTION

Sepsis is a major global healthy issue characterized by dysregulated immune and inflammatory responses to infecting pathogens as well as life-threatening multiple organ dysfunction.\(^1\) As a common complication of sepsis, acute respiratory distress syndrome (ARDS) clinically presents as acute pulmonary edema, reduced lung compliance, refractory hypoxemia, and ultimately respiratory failure with a high mortality rate of approximately 40%.\(^2,3\) In addition, ARDS also occurs in the setting of pneumonia, aspiration of gastric/oral/esophageal contents or trauma.\(^3\) Despite the substantial progress in the optimization of supportive care for ARDS (including lung-protective mechanical ventilation and fluid-conservative therapy) after decades of dedicated effort in experimental and clinical investigations, the search for specific pharmacological therapy that effectively treat ARDS has been fruitless due to clinical/biological heterogeneity of the syndrome and a lack of specific/effective biomarkers for risk-stratifying ARDS patients.\(^3,5\) In an attempt to overcome this challenge, the search of promising biomarkers for facilitating the recognition of ARDS and the improvement of clinical outcomes is necessary.

Long non-coding maternally expressed gene 3 (LncRNA MEG3), located within the imprinted DLK1-DIO3 gene cluster at chromosome 14q32.3, is initially identified as a lncRNA with the function of tumor suppressor.\(^6,7\) Recent researches reveal that LncRNA MEG3 is involved in the regulation of lung injury through regulating multiple inflammation-relative signaling pathways and apoptosis-related pathways such as caspase-1 signaling and Janus kinases/signal transducer and activator of transcription proteins.\(^8-11\) Meanwhile, LncRNA MEG3 exhibited the potential as a biomarker for identifying disease risk and progression of respiratory disease asthma.\(^12\) As for sepsis, LncRNA MEG3 modulates the pulmonary inflammatory responses to affect the initiation and progression of sepsis, and it displays the clinical implication in predicting prognosis in sepsis patients.\(^13-15\) In view of above-mentioned facts, it was speculated that LncRNA MEG3 might exhibit the clinical value for identifying ARDS risk in sepsis patients, while relevant report is lack. Therefore, the present study was to evaluate the potential of LncRNA MEG3 in predicting ARDS risk and its correlation with prognosis in sepsis patients.

2 | MATERIALS AND METHODS

2.1 | Participants

This study consecutively enrolled 112 sepsis patients from our hospital between January 2018 and September 2019. The screening criteria were as follows: (a) diagnosed as sepsis patients according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)\(^16\); (b) age ≥ 18 years old; (c) admitted to intensive care unit (ICU) within the previous 24 hours; (d) not complicated with other fatal diseases (eg, hematologic malignancies, solid tumors, or acquired immune deficiency syndrome); (e) without immunosuppressive therapy within 3 months before enrollment; (f) not in pregnancy or lactation. In addition, 100 healthy subjects underwent health examination in our hospital during October 2019 and December 2019 were recruited as healthy controls (HCs). All HCs had age and gender matched with the sepsis patients, no obvious abnormalities in biochemical indexes, and no history of hematological malignancies, solid tumors, sepsis, or other severe infections. This study was approved by the Institutional Review Board of our hospital. All participants or their family members provided the written informed consent before enrollment.

2.2 | Date collection

Sepsis patients’ clinical characteristics were recorded after admission, which included demographic characteristics, complications, primary infection site, primary organism, biochemical indexes, and disease severity. The severity of sepsis was assessed within 24 hours after admission using the acute pathologic and chronic health evaluation (APACHE) II score and sequential organ failure assessment (SOFA) score.

2.3 | Sample collection

The peripheral blood (PB) samples of sepsis patients were collected within 24 hours after admission, and the PB samples of HCs were obtained at enrollment. After collection, the PB samples were centrifuged at 3000 g for 15 minutes under 4°C to separate plasma. Then, the plasma samples were preserved at ~80°C for next detection. The expression of LncRNA MEG3 in plasma samples was detected using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

2.4 | RT-qPCR

The procedures of RT-qPCR were carried out in consistent with the method described in our previous study.\(^17\) The primers used in RT-qPCR were designed referring to the study published previously.\(^18\) and the details were as follows: LncRNA MEG3, forward primer: GCCCTGACCTTTGCTATGCT, reverse primer: TCGCACAAGACTGACACCCC; GAPDH, forward primer: TGACCACAGTCCATGCCATCAC, reverse primer: GCCTGCTTCAC CACCTTCTTGA. Besides, the reproducibility of GAPDH and LncRNA MEG3 results was evaluated. In sepsis patients, the median Ct value of LncRNA MEG3 was 21.9 and the inter-assay CV in all samples was 2.0%; the median Ct value of GAPDH was 19.1 and the inter-assay CV in all samples was 1.2% (Table S1). In HCs, the median Ct value of LncRNA MEG3 was 22.5 and the inter-assay CV in all samples was 1.1%; the median Ct value of GAPDH was 18.4 and the inter-assay...
CV in all samples was 1.7%. These findings indicated that the reproducibility was relatively good.

2.5 | Acute respiratory distress syndrome (ARDS) assessment

During hospitalization, intensive surveillance was given to the sepsis patients, and sepsis-related ADRS was monitored in time. The sepsis-related ADRS was assessed from three items according to Berlin definition of ARDS, which included (a) timing, within 1 week of a known clinical insult or new or worsening respiratory symptoms; (b) chest imaging, bilateral opacities (not fully explained by effusions, lobar/lung collapse, or nodules); (c) origin of edema, respiratory failure (not fully explained by cardiac failure or fluid overload). All sepsis patients were followed up to death or 28 days after admission. During follow-up, survival status of the sepsis patients was recorded, and all sepsis patients were classified as 28-day survivors and 28-day deaths. Meanwhile, accumulating mortality was calculated from the date of admission to the date of death or completion of the 28-day follow-up.

2.6 | Statistical analysis

SPSS 24.0 software (IBM) was used for statistical analyses, and GraphPad Prism 7.01 software (GraphPad software Inc.) was used to plot figures. Continuous data were expressed as mean ± standard deviation (SD) or median with interquartile range (IQR). Categorical data were described as number (percentage). Student’s t test, chi-square test, or Wilcoxon rank-sum test was used to compare the difference of variables between two groups. Spearman’s rank correlation test was used to analyze the correlation between two variables. Receiver-operating characteristic (ROC) curve was plotted, and the area under the curve (AUC), the sensitivity and specificity at the best cut-off point were used to assess the ability of variables in distinguishing different subjects. Kaplan-Meier method was used to describe accumulating mortality, and the difference of accumulating mortality between two groups was determined by the log-rank test. Univariate logistic regression model was used to analyze the risk factors of ARDS in sepsis patients, and forward stepwise multivariate logistic regression model was used to predict the independent risk factors of ARDS in sepsis patients. P value < .05 was considered statistically significant. Notably, we initially performed different ways of multivariate logistic regression analyses (including enter, backward and forward stepwise multivariate logistic regression analyses). By multivariate logistic regression analysis with “Enter” method, it did not work due to the relatively small sample size and the relatively large number of covariates. Then, we performed forward stepwise multivariate logistic regression analysis and backward stepwise multivariate logistic regression analysis, respectively, which found that the results were similar. Hence, we consulted a biostatistician and chosen forward stepwise multivariate logistic regression analysis.

| TABLE 1 | Patient’s characteristics |
|---------------------------------|---------------------------|
| Items                           | Sepsis patients (N = 112) |
| Age (y), mean ± SD              | 54.6 ± 11.0               |
| Gender, No. (%)                 |                           |
| Female                          | 46 (41.1)                 |
| Male                            | 66 (58.9)                 |
| BMI (kg/m²), mean ± SD          | 22.6 ± 3.6                |
| Smoke, No. (%)                  | 39 (34.8)                 |
| COPD, No. (%)                   | 22 (19.6)                 |
| Cardiomyopathy, No. (%)         | 49 (43.8)                 |
| Chronic kidney failure, No. (%) | 18 (16.1)                 |
| Cirrhosis, No. (%)              | 22 (19.6)                 |
| Primary infection site, No. (%) |                           |
| Abdominal infection             | 40 (35.7)                 |
| Respiratory infection           | 25 (22.3)                 |
| Skin and soft tissue infection  | 22 (19.6)                 |
| Blood stream infection          | 12 (10.7)                 |
| CNS infection                   | 6 (5.4)                   |
| Other infections                | 7 (6.3)                   |
| Primary organism, No. (%)       |                           |
| G− bacteria                     | 61 (54.5)                 |
| G+ bacteria                     | 25 (22.3)                 |
| Anaerobes                       | 12 (10.7)                 |
| Fungus                          | 7 (6.3)                   |
| Mycoplasmas                     | 5 (4.5)                   |
| Total culture negative          | 22 (19.6)                 |
| Biochemical indexes, median (IQR)|                       |
| Scr (mg/dL)                     | 1.8 (1.2-2.6)             |
| Albumin (g/L)                   | 27.1 (23.2-37.0)          |
| WBC (10⁹/L)                     | 18.3 (11.6-27.3)          |
| CRP (mg/L)                      | 97.6 (44.5-137.2)         |
| Disease severity, median (IQR)  |                           |
| APACHE II score                 | 13.0 (8.2-17.0)           |
| SOFA score                      | 6.0 (4.0-8.0)             |

Abbreviations: APACHE II, acute physiology and chronic health evaluation II; BMI, body mass index; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; G−, Gram-negative; G+, Gram-positive; IQR, interquartile range; Scr, serum creatinine; SD, standard deviation; SOFA, sequential organ failure assessment; WBC, white blood cell.

3 | RESULTS

3.1 | Clinical characteristics of sepsis patients

The mean age was 54.6 ± 11.0 years in sepsis patients, and there were 46 (41.1%) females and 66 (58.9%) males (Table 1). For chronic complications, 22 (19.6%), 49 (43.8%), 18 (16.1%), and 22 (19.6%) sepsis patients had chronic obstructive pulmonary disease (COPD),
FIGURE 1 LncRNA MEG3 distinguished sepsis patients from HCs. Comparison of lncRNA MEG3 relative expressions between HCs and sepsis patients (A). ROC curve analysis for the performance of lncRNA MEG3 in discriminating sepsis patients from HCs (B). LncRNA MEG3, long non-coding RNA maternally expressed gene 3; HCs, healthy controls; ROC, receiver operating characteristic.

TABLE 2 Comparison of characteristics between non-ARDS sepsis patients and ARDS sepsis patients

| Items                          | Non-ARDS sepsis patients | ARDS sepsis patients | P value |
|-------------------------------|--------------------------|----------------------|---------|
| Age (y), mean ± SD            | 53.3 ± 11.5              | 58.1 ± 8.5           | .040    |
| Gender, No. (%)               |                          |                      | .150    |
| Female                        | 37 (45.1)                | 9 (30.0)             |         |
| Male                          | 45 (54.9)                | 21 (70.0)            |         |
| BMI, (kg/m²), mean ± SD       | 22.5 ± 3.6               | 23.0 ± 3.4           | .500    |
| Smoke, No. (%)                | 23 (28.0)                | 16 (53.3)            | .013    |
| COPD, No. (%)                 | 11 (13.4)                | 11 (36.7)            | .006    |
| Cardiomyopathy, No. (%)       | 35 (42.7)                | 14 (46.7)            | .707    |
| Chronic kidney failure, No. (%)| 11 (13.4)                | 7 (23.3)             | .206    |
| Cirrhosis, No. (%)            | 17 (20.7)                | 5 (16.7)             | .632    |
| Primary infection site, No. (%)|                        |                      |         |
| Abdominal infection           | 33 (40.2)                | 7 (23.3)             | .989    |
| Respiratory infection         | 12 (14.6)                | 13 (43.3)            | .001    |
| Skin and soft tissue infection| 16 (19.5)                | 6 (20.0)             | .954    |
| Blood stream infection        | 10 (12.2)                | 2 (6.7)              | .402    |
| CNS infection                 | 4 (4.9)                  | 2 (6.7)              | .710    |
| Other infections              | 7 (8.5)                  | 0 (0.0)              | .098    |
| Primary organism, No. (%)     |                          |                      |         |
| G– bacteria                   | 44 (53.7)                | 17 (56.7)            | .777    |
| G+ bacteria                   | 17 (20.7)                | 8 (26.7)             | .504    |
| Anaerobes                     | 8 (9.8)                  | 4 (13.3)             | .588    |
| Fungus                        | 5 (6.1)                  | 2 (6.7)              | .912    |
| Mycoplasmas                   | 4 (4.9)                  | 1 (3.3)              | .726    |
| Total culture negative        | 17 (20.7)                | 5 (16.7)             | .632    |
| Biochemical indexes, median (IQR) |                      |                      |         |
| Scr (mg/dL)                   | 1.9 (1.2-2.7)            | 1.6 (1.2-2.7)        | .606    |
| Albumin (g/L)                 | 27.2 (23.0-35.7)         | 26.6 (23.1-35.5)     | .559    |
| WBC (10⁹/L)                   | 15.8 (11.3-27.1)         | 22.6 (13.0-28.5)     | .114    |
| CRP (mg/L)                    | 72.5 (42.9-127.4)        | 132.3 (68.8-226.1)   | .003    |
| Disease severity, median (IQR)|                        |                      |         |
| APACHE II score               | 12.0 (7.0-16.3)          | 14.0 (10.8-18.3)     | .030    |
| SOFA score                    | 5.0 (4.0-8.0)            | 7.0 (5.0-10.0)       | .008    |

Note: Comparison was determined by Student’s t test, chi-square test or Wilcoxon rank-sum test.
Abbreviations: APACHE II, acute physiology and chronic health evaluation II; ARDS, acute respiratory distress syndrome; BMI, body mass index; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; G–, Gram-negative; G+, Gram-positive; IQR, interquartile range; Scr, serum creatinine; SD, standard deviation; SOFA, sequential organ failure assessment; WBC, white blood cell.
cardiomyopathy, chronic kidney failure, and cirrhosis, respectively. In addition, 40 (35.7%), 25 (22.3%), 22 (19.6%), 12 (10.7%), 6 (5.4%), and 7 (6.3%) sepsis patients exhibited abdominal infection, respiratory infection, skin and soft tissue infection, blood stream infection, central nervous system infection, and other infections, respectively. Meanwhile, 61 (54.5%), 25 (22.3%), 12 (10.7%), 7 (6.3%), 5 (4.5%), and 22 (19.6%) sepsis patients were with G− bacteria, G+ bacteria, anaerobes, fungus, mycoplasmas, and total culture negative as primary organism, respectively. Besides, the median APACHE II score was 13.0 (8.2-17.0) and the median SOFA score was 6.0 (4.0-8.0) in sepsis patients. The detailed information regarding other characteristics such as body mass index (BMI) and biochemical indexes was disclosed in Table 1.

3.2 | The value of lncRNA MEG3 for distinguishing sepsis patients from HCs

The lncRNA MEG3 relative expression was 2.317 (1.889-3.336) in sepsis patients and 0.990 (0.655-1.306) in HCs, and further comparison analysis showed that lncRNA MEG3 relative expression was increased in sepsis patients compared with HCs (P < .001) (Figure 1A).

The following ROC curve exhibited that lncRNA MEG3 could differentiate sepsis patients from HCs with an AUC of 0.893 (95% CI: 0.849-0.936). At the best cut-off point (lncRNA MEG3 = 1.782; the point at which the sum of sensitivity and specificity was the largest), the sensitivity was 77.7% and the specificity was 94.0% (Figure 1B).

3.3 | Clinical characteristics of non-ARDS sepsis patients and ARDS sepsis patients

During 28-day follow-up period, 30 (26.8%) sepsis patients occurred ARDS, and they were grouped as ARDS sepsis patients; 82 (73.2%) patients did not occur ARDS, and they were grouped as non-ARDS sepsis patients. The median time of occurrence of ARDS after onset sepsis was 2.5 (2.0-4.0) days. The following comparisons analyses displayed that ARDS sepsis patients presented older age (P = .040), elevated percentage of smoking cases (P = .013), percentage of COPD cases (P = .006), percentage of respiratory infection cases (P = .001), increased C-reactive protein (CRP) (P = .003), APACHE II score (P = .030), and SOFA score (P = .008) compared with non-ARDS sepsis patients (Table 2).

3.4 | The value of lncRNA MEG3 for predicting ARDS risk in sepsis patients

LncRNA MEG3 relative expression was higher in ARDS patients than that in non-ARDS patients (P < .001) (Figure 2A). Subsequent ROC curve showed that lncRNA MEG3 could predict ARDS risk in sepsis patients with an AUC of 0.775 (95% CI: 0.678-0.872) (Figure 2B). At the best cut-off point (lncRNA MEG3 = 2.259; The point at which the sum of sensitivity and specificity was the largest), the sensitivity was 86.7% and the specificity was 58.5%.

3.5 | Risk factors for ARDS in sepsis patients

Univariate logistic regression analysis displayed that lncRNA MEG3 (P < .001, OR = 2.058), age (P = .043, OR = 1.043), smoke (P = .015, OR = 2.932), COPD (P = .008, OR = 3.737), primary infection site (respiratory vs others) (P = .002, OR = 4.461), CRP (P = .001, OR = 1.011), and SOFA score (P = .005, OR = 1.235) were risk factors of ARDS in sepsis patients (Table 3), and further forward stepwise multivariate logistic regression analysis showed that lncRNA MEG3 (P = .004, OR = 1.869), age (P = .044, OR = 1.063), smoke (P = .007, OR = 5.114), and CRP (P = .003, OR = 1.012) were independent risk factors for ARDS in sepsis patients. These independent risk factors were used to construct the predictive model for ARDS risk in sepsis patients (including lncRNA MEG3, age, smoke, and CRP), then the following ROC curve analysis manifested that the predictive model exhibited a good value for identifying ARDS risk in sepsis patients (AUC: 0.851, 95% CI: 0.776-0.926) (Figure 3).

FIGURE 2 LncRNA MEG3 predicted ARDS risk in sepsis patients. Comparison of lncRNA MEG3 relative expressions between ARDS sepsis patients and non-ARDS sepsis patients (A). ROC curve analysis for the performance of lncRNA MEG3 for predicting ARDS risk in sepsis patients (B). LncRNA MEG3, long non-coding RNA maternally expressed gene 3; HCs, healthy controls. ARDS, acute respiratory distress syndrome; ROC, receiver operating characteristic.
TABLE 3  Analysis of risk factors of ARDS in sepsis patients

| Items                                      | Logistic regression model            |         | OR    | 95% CI Lower | 95% CI Higher |
|--------------------------------------------|--------------------------------------|---------|-------|--------------|---------------|
| **Univariate logistic regression**         |                                      | P value |       |              |               |
| LncRNA MEG3                                | <.001                                | 2.058   | 1.448 | 2.926        |               |
| Age                                        | .043                                 | 1.043   | 1.001 | 1.086        |               |
| Male                                       | .153                                 | 1.919   | 0.785 | 4.690        |               |
| BMI                                        | .497                                 | 1.042   | 0.926 | 1.171        |               |
| Smoke                                      | .015                                 | 2.932   | 1.236 | 6.956        |               |
| COPD                                       | .008                                 | 3.737   | 1.407 | 9.289        |               |
| Cardiomyopathy                            | .707                                 | 1.175   | 0.507 | 2.722        |               |
| Chronic kidney failure                     | .211                                 | 1.964   | 0.682 | 5.658        |               |
| Cirrhosis                                  | .632                                 | 0.765   | 0.255 | 2.294        |               |
| Primary infection site (Respiratory vs others) |                                     | .002     | 4.461 | 1.731        | 11.498        |
| **Primary infection organism**             |                                      |         |       |              |               |
| G- vs. others                             | .777                                 | 1.129   | 0.486 | 2.623        |               |
| G+ vs. others                             | .505                                 | 1.390   | 0.527 | 3.666        |               |
| Anaerobes/fungus/mycoplasmas vs. others    | .658                                 | 1.255   | 0.459 | 3.437        |               |
| Scr                                        | .465                                 | 0.888   | 0.647 | 1.220        |               |
| Albumin                                   | .409                                 | 0.980   | 0.936 | 1.027        |               |
| WBC                                        | .183                                 | 1.027   | 0.987 | 1.069        |               |
| CRP                                        | .001                                 | 1.011   | 1.005 | 1.017        |               |
| APACHE II                                 | .106                                 | 1.058   | 0.988 | 1.133        |               |
| SOFA score                                 | .005                                 | 1.235   | 1.067 | 1.430        |               |
| **Forward stepwise multivariate logistic regression** |                                      | .004     | 1.869 | 1.222        | 2.860        |
| LncRNA MEG3                                |                                      |         |       |              |               |
| Age                                        | .044                                 | 1.063   | 1.002 | 1.127        |               |
| Smoke                                      | .007                                 | 5.114   | 1.567 | 16.687       |               |
| CRP                                        | .003                                 | 1.012   | 1.004 | 1.020        |               |

Note: Risk factors of ARDS were analyzed by univariate logistic regression model, and the independent risk factors were analyzed by forward stepwise multivariate logistic regression model.

Abbreviations: APACHE II, acute physiology and chronic health evaluation II; ARDS, acute respiratory distress syndrome; BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; G-, Gram-negative; G+, Gram-positive; LncRNA MEG3, long non-coding RNA maternally expressed gene 3; OR, odds ratio; Scr, serum creatinine; SOFA, sequential organ failure assessment; WBC, white blood cell.

*One unit increase in the LncRNA MEG3 expression would elevate the risk of ARDS 2.058 times in sepsis patients. The model was as follows: P = exp [-8.633 + 0.625 * (LncRNA MEG3) + 0.061 * (age) + 1.632 * (smoke) + 0.012 * (CRP)]/1 + exp [-8.633 + 0.625 * (LncRNA MEG3) + 0.061 * (age) + 1.632 * (smoke) + 0.012 * (CRP)]. Goodness of fit: −2ln(R) = 84.968, Nagelkerke $R^2$ = 0.483.

**3.6 | Correlation of LncRNA MEG3 with primary infection site in sepsis patients**

LncRNA MEG3 was positively correlated with respiratory infection ($P = .005$) (Figure 4B), while it was not correlated with abdominal infection ($P = .375$) (Figure 4A), skin and soft tissue infection ($P = .158$) (Figure 4C), blood stream infection ($P = .569$) (Figure 4D), or CNS infection ($P = .369$) (Figure 4E) in sepsis patients.

**3.7 | Correlation of LncRNA MEG3 with complications, primary infection site, primary organism biochemical indexes, and disease severity in sepsis patients**

LncRNA MEG3 was positively correlated with COPD ($P = .014$) (Table 4), white blood cell (WBC) ($P = .008, r = 0.248$), CRP ($P = .001, r = 0.300$) (Table 5), APACHE II score ($P < .001, r = 0.440$) (Figure 5A), and SOFA score ($P < .001, r = 0.366$) (Figure 5B), while negatively correlated albumin ($P < .001, r = -0.325$) (Table 5) in sepsis patients.

**3.8 | The value of LncRNA MEG3 for predicting 28-day mortality risk in sepsis patients**

During the 28-day follow-up duration, there were 83 (74.1%) 28-day survivors and 29 (25.9%) 28-day deaths, then the following comparison analysis revealed that LncRNA MEG3 expression was raised in 28-day deaths compared with 28-day survivors ($P < .001$) (Figure 6A). Furthermore, ROC curve displayed that the predictive value of LncRNA MEG3 (AUC: 0.708, 95% CI: 0.608-0.808) for 28-day mortality risk in sepsis patients was non-inferior to common biochemical indexes such as Scr (AUC: 0.694, 95% CI: 0.590-0.798), albumin (AUC: 0.629, 95% CI: 0.511-0.748), WBC (AUC: 0.637, 95% CI: 0.533-0.741), and CRP (AUC: 0.757, 95% CI: 0.611-0.853), while less than common comprehensive score such as APACHE II score (AUC: 0.799, 95% CI: 0.707-0.891) and SOFA score (AUC: 0.848, 95% CI: 0.767-0.929) (Figure 6B). In addition, the accumulating mortality was elevated in sepsis patients with LncRNA MEG3 high expression compared to those with LncRNA MEG3 low expression ($P = .005$) (Figure 7).

**4 | DISCUSSION**

Preceding researches identified LncRNA MEG3 as a regulator for lung injury through modulating inflammatory signaling pathways or cell apoptosis-related pathways in multiple inflammatory diseases.8-11 As an example, Zou et al unravel that LncRNA MEG3 knockdown attenuates cell damage to subsequently attenuate hyperoxia-induced lung injury via inhibiting non-obese diabetic-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activity...
Another study illuminates that lncRNA MEG3 induces pulmonary microvascular endothelial cell apoptosis via the upregulation of caspase-3 activity, reduction of Bcl-2 level, and elevation of Bax in chronic obstructive pulmonary disease. Meanwhile, lncRNA MEG3 has a good predictive value for disease risk of respiratory disease asthma. In addition, lncRNA MEG3 up-regulates IL-1β abundance and exaggerates inflammatory responses in alveolar macrophages and lung epithelial cells, which is involved in the progression of sepsis, and clinically, lncRNA MEG3 is proved to be associated with higher mortality risk in sepsis patients. While the clinical value of lncRNA MEG3 in sepsis-related ARDS is still unknown.

In the present study, lncRNA MEG3 expression was higher in sepsis patients than that in HCs, and it could distinguish sepsis patients from HCs. The findings could be explained by first, lncRNA MEG3 might promote the expression of inflammatory cytokines CRP, IL-1β, IL-6, and monocyte chemoattractant protein-1, which subsequently intensified inflammatory response in
TABLE 4  Correlation of lncRNA MEG3 with complications and primary organism

| Items                        | LncRNA MEG3 expression | P value |
|------------------------------|------------------------|---------|
| Complications, median (IQR)  |                        |         |
| COPD No                      | 2.259 (1.804-3.164)    | .014    |
| COPD Yes                     | 3.214 (2.017-5.176)    |         |
| Cardiomyopathy No            | 2.373 (1.893-3.321)    | .626    |
| Cardiomyopathy Yes           | 2.221 (1.605-4.012)    |         |
| Chronic kidney failure No    | 2.325 (1.890-3.273)    | .659    |
| Chronic kidney failure Yes   | 2.247 (1.734-4.189)    |         |
| Cirrhosis No                 | 2.317 (1.890-3.326)    | .858    |
| Cirrhosis Yes                | 2.568 (1.704-3.425)    |         |

Primary organism, median (IQR)

| Items                  | LncRNA MEG3 expression | P value |
|------------------------|------------------------|---------|
| G− bacteria No         | 2.289 (1.520-3.293)    | .515    |
| G− bacteria Yes        | 2.361 (1.911-3.368)    |         |
| G+ bacteria No         | 2.407 (1.896-3.395)    | .125    |
| G+ bacteria Yes        | 2.073 (1.362-2.458)    |         |
| Anaerobes/fungus/mycoplasmas No | 2.361 (1.895-3.456) | .245    |
| Anaerobes/fungus/mycoplasmas Yes | 2.102 (1.436-2.941) |         |

Note: Comparison was determined by Wilcoxon rank-sum test.
Abbreviations: COPD, chronic obstructive pulmonary disease; G−, Gram-negative; G+, Gram-positive; IQR, interquartile range; lncRNA MEG3, long non-coding RNA maternally expressed gene 3.

TABLE 5  Correlation of lncRNA MEG3 with biochemical indexes in sepsis patients

| Items   | Correlation coefficient (r) | P value |
|---------|-----------------------------|---------|
| Scr     | 0.152                       | .110    |
| Albumin | −0.325                      | <.001   |
| WBC     | 0.248                       | .008    |
| CRP     | 0.300                       | .001    |

Note: Correlation was determined by Spearman’s rank correlation test.
Abbreviations: CRP, C-reactive protein; lncRNA MEG3, long non-coding RNA maternally expressed gene 3; Scr, serum creatinine; WBC, white blood cell.

Interestingly, the prognostic value of lncRNA MEG3 for 28-day mortality risk in sepsis patients was non-inferior to common biochemical indicators such as Scr, albumin, WBC, and CRP, while cell apoptosis in major organs including kidney and heart, which subsequently accelerated multiple organ injury in sepsis, thereby, lncRNA MEG3 was elevated in sepsis patients compared with HCs.20 Second, lncRNA MEG3 probably mediated...
less than common comprehensive score such as APACHE II score and SOFA score, which was implied that lncRNA MEG3 displayed the potential of being an additional prognostic biomarker for sepsis patients' outcome in clinical setting.

Several shortcomings should be noted when interpreting the findings of the present study. First, the lncRNA MEG3 expression was only detected at a single time (within 24 hours after admission) in sepsis patients, further study assessing the variation of lncRNA MEG3 through the course of disease and treatment was necessary. Second, the sample size of ARDS-sepsis patients included in the analysis was relatively small (n = 30), which might reduce the statistic power; thereby, further study with larger sample size was needed for validate our findings. Third, only 28-day mortality was evaluated in sepsis patients; thereby, further study with extended follow-up duration for exploring the long-term predictive value of lncRNA MEG3 for prognosis would be warranted. Last, only one inflammatory index (CRP) was assessed and included in the analysis, further studies with the detection of more inflammatory indexes (such as TNF-α, IL-6, and IL-1β) in sepsis patients were needed for indicating inflammation more comprehensively.

To conclude, circulating lncRNA MEG3 is correlated with higher ARDS risk and elevated accumulating mortality in sepsis patients, which offers a new perspective for optimizing prevention strategies against ARDS and improving prognosis in sepsis.
ACKNOWLEDGMENTS
This study was supported by Natural Science Foundation of Hubei Province (No. 2017CFC851).

CONFLICT OF INTEREST
No potential conflict of interest was reported by the authors.

ORCID
Li Yu https://orcid.org/0000-0003-4116-7045

REFERENCES
1. Rudd KE, Johnson SC, Aagesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211.

2. Weinacker AB, Vaszar LT. Acute respiratory distress syndrome: physiology and new management strategies. Annu Rev Med. 2001;52(1):221-237.

3. Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18.

4. Englert JA, Bobba C, Baron RM. Integrating molecular pathogenesis and clinical translation in sepsis-induced acute respiratory distress syndrome. JCI Insight. 2019;4(2):e124061.

5. Bime C, Casanova N, Oita RC, et al. Development of a biomarker mortality risk model in acute respiratory distress syndrome. Crit Care. 2019;23(1):410.

6. Zhang L, Wang H. Long non-coding RNA in CNS injuries: a new target for therapeutic intervention. Mol Ther Nucleic Acids. 2019;17:754-766.

7. Ghafouri-Fard S, Taheri M. Maternally expressed gene 3 (MEG3): a tumor suppressor long non coding RNA. Biomed Pharmacother. 2019;118:109129.

8. Sun Z, Nie X, Sun S, et al. Long non-coding RNA MEG3 downregulation triggers human pulmonary artery smooth muscle cell proliferation and migration via the p53 signaling pathway. Cell Physiol Biochem. 2017;42(6):2569-2581.

9. Li X, Zhang Q, Yang Z. Silence of MEG3 intensifies lipopolysaccharide-stimulated damage of human lung cells through modulating miR-4262. Artif Cells Nanomed Biotechnol. 2019;47(1):2369-2378.

10. Zou D-M, Zhou S-M, Li L-H, et al. Knockdown of long noncoding RNAs of maternally expressed 3 alleviates hyperoxia-induced lung injury via inhibiting thioredoxin-interacting protein-mediated pyroptosis by binding to miR-18a. Am J Pathol. 2020;190(5):994-1005.

11. Bi H, Wang G, Li Z, et al. Noncoding RNA (IncRNA) maternally expressed gene 3 (MEG3) participates in chronic obstructive pulmonary disease through regulating human pulmonary microvascular endothelial cell apoptosis. Med Sci Monit. 2020;26:e920793.

12. Feng Y, Yang C, Yan W. Expression of IncRNA MEG3 in asthma with different phenotypes and its relationship with course of disease. Exp Ther Med. 2020;19(3):2211-2217.

13. Li R, Fang L, Pu Q, et al. MEG3-4 is a miRNA decoy that regulates IL-1beta abundance to initiate and then limit inflammation to prevent sepsis during lung infection. Sci Signal. 2018;11(536):eaao2387.

14. Na L, Ding H, Xing E, et al. Lnc-MEG3 acts as a potential biomarker for predicting increased disease risk, systemic inflammation, disease severity, and poor prognosis of sepsis via interacting with miR-21. J Clin Lab Anal. 2020;34(4):e23123.

15. Chen K, Shi X, Jin YE, et al. High IncRNA MEG3 expression is associated with high mortality rates in patients with sepsis and increased lipopolysaccharide-induced renal epithelial cell and cardiomyocyte apoptosis. Exp Ther Med. 2019;18(5):3943-3947.

16. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-810.

17. Geng F, Liu W, Yu L. Potential role of circulating long noncoding RNA MALAT1 in predicting disease risk, severity, and patients’ survival in sepsis. J Clin Lab Anal. 2019;33(8):e22968.

18. Lyu Y, Lou J, Yang Y, et al. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. Leukemia. 2017;31(12):2545-2551.

19. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533.

20. Zha F, Xu Q, Tang BO, et al. Long non-coding RNA MEG3 promotes fibrosis and inflammatory response in diabetic nephropathy via miR-181a/Egr-1/TLR4 axis. Aging (Albany NY). 2019;11(11):3716-3730.

21. Zhang WW, Geng X, Zhang WQ. Downregulation of IncRNA MEG3 attenuates high glucose-induced cardiomyocytes injury by inhibiting mitochondria-mediated apoptosis pathway. Eur Rev Med Pharmacol Sci. 2019;23(17):7599-7604.

22. Tang S, Han J, Jiao H, Si J, Liu Y, Wang J. Long noncoding RNA MEG3 deteriorates inflammatory damage by downregulating microRNA-101a. J Cell Biochem. 2020;121(2):1801-1810.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.